Most Recent
AstraZeneca has attacked generic drugmaker Pharmacor’s challenge to a patent extension for its diabetes drug Forxiga, telling a judge that it hinges on the false notion that the protected IP is limited to a single molecule.
AstraZeneca has denied claims by Pharmacor that a patent for its diabetes drug Forxiga is invalid and that an extension of the patent's term was wrongly granted.
Teen fashion label White Fox will claim a pair of shorts that bore a four-stripe design was merely ‘decorative’ and did not infringe on Adidas’ distinctive three-stripe trade mark, a court has heard.
Pfizer has lost a patent infringement lawsuit against Samsung Bioepis over the generic version of its blockbuster autoimmune drug Enbrel, with a judge finding all but one of the patent's claims is invalid.
Industry standards group Meat & Livestock Australia can bring a cross-claim for indemnity against the Agricultural Business Research Institute while defending a case alleging it infringed a patent for inferring bovine gene traits.
Storage King has failed in its opposition to a trade mark application by Sydney-based Rubbish Removal Kings, with IP Australia saying 'king' was a “common laudatory word".
Swiss drug maker Novartis has lost its bid to have Pharmacor's Valtresto trade mark removed for non use, with an IP Australia delegate finding that an injunction in a fight over the patent for Novartis' heart drug Entresto was an obstacle to using the mark.
AstraZeneca has slammed Pharmacor's defence to claims it infringed a patent for blockbuster diabetes drug Forxiga as a "complete shot in the dark", as the drug maker unsuccessfully fought orders to produce documents from a UK case.
Trial in AstraZeneca's patent infringement case over Pharmacor's plans to launch a cheaper version of diabetes drug Forxiga has been delayed to October, after the generic drug maker got the all-clear to revise its cross-claim.
Pharmacor, which is facing infringement claims by AstraZeneca over its plans to launch a generic version of diabetes drug Forxiga, can tweak its cross-claim to challenge a patent term extension.